Oral Cavity
12
2
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.3%
1 terminated out of 12 trials
88.9%
+2.3% vs benchmark
25%
3 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma
Spectroscopic Analysis of Tongue Tumor Samples.
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
PuraBond® and Pain Following Resection of Oral or Oropharyngeal Mucosal Lesions
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
Oral Health and Fundamental of Care Program
Perioperative Supplementation With Immunonutrition and Its Impact on Surgical Outcome and Pain in Oral Cavity or Mandibular Tumours
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
The Influence of Bisphosphonates in the Oral Cavity in Children
Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients
Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma